Conclusions
HCC
REMISSIONS
This phase 1b/2 study confirmed that the combination of GT90001 (7.0 mg/kg, every 2 weeks) and nivolumab had a manageable safety profile in patients with advanced HCC. Additionally, the regimen demonstrated promising anti-tumor activity, showing durable remissions and objective responses in this population. This finding suggested that this combination might be a potential treatment option for advanced HCC.